Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 17/11/2017
SIETES contiene 92128 citas

 
 
 1 a 20 de 289 siguiente >>
Presentar resultados
Seleccionar todas
1. Cita con resumen
Bromley RL, Weston J, Marson AG. Maternal use of antiepileptic agents during pregnancy and major congenital malformations in children. JAMA 2017;318:1700-1. [Ref.ID 102140]
2. Cita con resumen
Persson M, Cnattingius S, Villamor E, Söderling J, Pasternak B, Stephansson O, Neovius M. Risk of major congenital malformations in relation to maternal overweight and obesity severity: cohort study of 1.2 million singletons. BMJ 2017;357:j2563. [Ref.ID 101639]
3. Cita con resumen
Casassus B. Drug scandals in France: have the lessons been learnt?. Lancet 2016;388:550-2. [Ref.ID 100574]
4.Enlace a cita original
Bérard A, Sheehy O, Zhao J-P, Nordeng H. Use of macrolides during pregnancy and rik of birth defects: a population-based study. Pharmacoepidemiol Drug Saf 2015;24:1241-8. [Ref.ID 99787]
6.Tiene citas relacionadas Cita con resumen
Clarke R, Bennett D. Folate and prevention of neural tube defects. BMJ 2014;349:g4810. [Ref.ID 98164]
7. Cita con resumen
Pastemak B, Svanström H, Molgaard-Nielsen D, Melbye M, Hviid A. Metoclopramide in pregnancy and risk of major congenital malformations and fetal death. JAMA 2013;310:1601-11. [Ref.ID 96391]
8. Cita con resumen
Colman E, Golden J, Roberts M, Egan A, Weaver J, Rosenbraugh C. The FDA's assessment of two drugs for chronic weight management. N Engl J Med 2012;367:1577-9. [Ref.ID 93939]
9.Enlace a cita original Cita con resumen
Anónimo. Change in the pregnancy category for topiramate. Australian Prescriber 2012;35:66. [Ref.ID 93159]
10.Tiene citas relacionadas Cita con resumen
Montastruc J-L, Sommet A, Bagheri H, Lapeyre-Mestre M. Benefits and strenghts of the disproportionality analysis of identification of adverse drug reactions in a pharmacovigilance database. Br J Clin Pharmacol 2011;72:905-8. [Ref.ID 91873]
12.Tiene citas relacionadas Cita con resumen
Mitchell AA. Fetal risk from ACE inhibitors in the first trimester. BMJ 2011;343:857-8. [Ref.ID 91753]
13. Cita con resumen
Roth C, Khan S, Sun Y, Hess K, Shmulevich I, Sood AK, Zhang W. Folic acid supplements in pregnancy and severe language delay in children. JAMA 2011;306:1566-73. [Ref.ID 91544]
15.Tiene citas relacionadas
Tomson T, Battino D, Perucca E. Major birth defects after exposure to newer-generation antiepileptic drugs. JAMA 2011;306:826-7. [Ref.ID 91017]
16.Tiene citas relacionadas
Merry L, Martin KL, Chen T. Major birth defects after exposure to newer-generation antiepileptic drugs. JAMA 2011;306:826. [Ref.ID 91016]
17. Cita con resumen
Tomson T, Battino D, Bonizzoni E, Craig J, Sabers DA, Perucca E, Vajda F, for the EURAP study group. Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry. Lancet Neurol 2011;10:609-17. [Ref.ID 90724]
18.Tiene citas relacionadas Cita con resumen
Molgaard-Nielsen D, Hviid A. Newer-generation antiepileptic drugs and the risk of major birth defects. JAMA 2011;305:1996-2002. [Ref.ID 90564]
Seleccionar todas
 
 1 a 20 de 289 siguiente >>